window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Gene Therapy

  • Advanced Therapies,Drug Delivery & Formulation,Drug Discovery & Development,Research & Development

    Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy

    Circio and Full Circles Therapeutics are combining circular RNA and [...]

    August 27, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1

    Lumen Bioscience has received up to $7m in US government [...]

    August 25, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Genespire starts international MMA study to support GENE202 development

    Genespire has started enrolling children with severe methylmalonic acidemia in [...]

    August 25, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Andelyn and Queen’s University partner on AAV9 gene therapy for GM2 gangliosidoses

    Andelyn Biosciences and Queen’s University have partnered to develop and [...]

    August 19, 2026
  • Advanced Therapies,Clinical & Regulatory,Digital & Data,Genomics and sequencing

    MaxCyte launches off-target assays for adenine and cytosine base editors

    MaxCyte has launched two sequencing-based assays to identify potential off-target [...]

    August 19, 2026
  • Advanced Therapies,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    VectorBuilder and Lir Therapeutics partner on AI-guided AAV capsid engineering

    VectorBuilder and Lir Therapeutics have entered a collaboration to optimise [...]

    August 19, 2026
  • Advanced Therapies,Central Nervous System,Genomics and sequencing,Research & Development

    Researchers develop electromagnetic gene switch for remote control of gene expression

    Researchers at Dongguk University in South Korea have developed an [...]

    August 17, 2026
  • Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Research & Development,Therapeutic Areas

    Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness

    Skylark Bio has dosed the first patient in a Phase [...]

    August 13, 2026
  • Advanced Therapies,Drug Discovery & Development,Genomics and sequencing

    Broken String Biosciences launches BaseMap ABE for genome-wide off-target analysis

    Broken String Biosciences has launched BaseMap ABE, a platform designed [...]

    August 10, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Research & Development

    Circio advances circular RNA gene therapy platform towards clinical development

    Circio is preparing to advance its circular RNA gene therapy [...]

    August 4, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MRI study suggests some prostate cancer biopsies could eventually be avoided
    Categories: Clinical & Regulatory, Medical devices, Research & Development, Therapeutic Areas
  • START and Allegheny Health Network to expand access to early-phase cancer trials
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Polaryx advances Phase 2 trial of PLX-200 in four rare diseases
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top